U.S. FDA Approves Bimekizumab-bkzx (Bimzelx, UCB) for HS
The Dermatology Digest
NOVEMBER 20, 2024
The U.S. Food and Drug Administration (FDA) has approved bimekizumab-bkzx (Bimzelx, UCB) for the treatment of adults with moderate-to-severe hidradenitis suppurativa (HS). Bimekizumab, an interleukin 17F (IL-17F) and IL-17A blocker, is now the third medication approved for HS, joining adalimumab (Humira, AbbVie) and its biosimilars and secukinumab (Cosentyx, Novartis). “The approval of BIMZELX in moderate-to-severe hidradenitis suppurativa is welcome given the substantial unmet clinical ne
Let's personalize your content